Epithalon, also written Epitalon, is the four-residue peptide Ala-Glu-Asp-Gly (AEDG), CAS 307297-39-8, synthesized within the Khavinson short-peptide program from the amino-acid composition of a bovine pineal extract. Cultured-cell papers report telomerase, telomere, and replicative-division observations, while animal papers report endocrine, tumor-model, and lifespan findings; the literature is investigator-concentrated and does not establish human longevity, clinical efficacy, general safety, a dose, or an approved therapeutic use.
Epithalon’s scientific story is inseparable from its source structure. A coherent body of work spans cell culture, pineal models, Drosophila, rodents, and transgenic mice, yet many headline papers come from Vladimir Khavinson, long-term collaborators, or connected institutions. This guide therefore treats publication, replication, and translation as three different questions.
Apex-specific research boundary: Apex Laboratory materials are research-grade chemical reagents supplied for in-vitro and preclinical research only. They are not pharmaceutical formulations, are not for human consumption, and are not represented here as anti-aging treatments, administration products, or substitutes for approved medicines.
- Epithalon/Epitalon identifies the AEDG tetrapeptide; sequence and registry fields establish identity, not telomerase activity, longevity, safety, or efficacy.
- The best-known telomerase and division-limit findings are cultured-cell results, including a 2025 cell-line update; human-derived cells do not make an experiment a human clinical study.
- Animal endocrine and lifespan papers answer model-specific questions, and a separate rat study reported no significant melatonin effect under its conditions.
- Most primary evidence comes from the originating research network, so source concentration and limited independent replication must remain visible.
What Is Epithalon (Epitalon)?
Epithalon and Epitalon are spelling variants used for the tetrapeptide Ala-Glu-Asp-Gly, abbreviated AEDG. The PubChem CID 219042 record maps it to formula C14H22N4O9, computed molecular weight 390.35 g/mol, and CAS RN 307297-39-8. Araj et al. (2025) provide a recent outside review of the AEDG literature and nomenclature.
| Field | Record | Interpretation boundary |
|---|---|---|
| Names | Epithalon / Epitalon | Spelling variants for AEDG in the cited record. |
| Sequence | Ala-Glu-Asp-Gly (A-E-D-G) | A defined four-residue chain; sequence does not establish activity. |
| Formula / MW | C14H22N4O9 / 390.35 g/mol | Computed registry fields, not current-lot results. |
| CAS / PubChem | 307297-39-8 / CID 219042 | Registry mapping; not approval, longevity evidence, safety, or efficacy. |
Where Did the Epithalon Research Program Come From?
Epithalon was developed within Vladimir Khavinson’s short-peptide bioregulator program in Saint Petersburg. A key lineage paper, Khavinson et al. (2017), reported analytical identification of AEDG in a pineal-gland polypeptide complex. Mass spectrometry and HPLC resolved that epiphysis complex into free amino acids (3.26%), dipeptides (23.19%), tripeptides (50.72%), tetrapeptides (22.10%) and pentapeptides (0.72%), with AEDG detected inside the tetrapeptide fraction by selective reaction monitoring. That composition ties the sequence to the studied pineal material. It does not by itself prove every proposed endocrine, gene-regulatory, telomerase, or longevity function.
The program’s continuity is scientifically useful: related hypotheses were pursued across models for decades. It is also a limitation — many primary papers share lead investigators or affiliated groups, and several are short reports. PubMed indexing confirms the bibliographic record; it does not supply independent replication, larger samples, stronger controls, or clinical translation.
What Do the Telomerase Studies Actually Show?
The most cited Epithalon claim begins in cell culture. Khavinson et al. (2003) added the peptide to telomerase-negative human fetal fibroblasts and reported induced expression of the telomerase catalytic subunit, enzymatic telomerase activity, and telomere elongation, with no effect size given in the indexed abstract. Khavinson et al. (2004) then quantified the proliferative consequence: primary pulmonary fibroblasts from a 24-week human fetus exhausted their proliferative potential at passage 34, while peptide-treated cells with re-elongated telomeres completed 10 further divisions and were still dividing at passage 44.
A recent update adds nuance rather than closing the gap. Al-Dulaimi et al. (2025) treated the breast-cancer lines 21NT and BT474 alongside normal human epithelial and fibroblast cells: qPCR and immunofluorescence showed dose-dependent telomere lengthening through hTERT mRNA and telomerase upregulation in the normal cells, and through alternative lengthening of telomeres (ALT) in the cancer lines, with only a minor ALT rise in normal cells.
These papers are often summarized as “human longevity evidence,” which collapses several steps. The cells were human-derived; the experiments stayed in vitro. A longer replicative span in culture is not a longer organism lifespan, and a telomerase signal does not establish whole-body exposure, durable telomere maintenance, or clinical benefit.
How Strong Are the DNA-Binding and Gene-Regulation Proposals?
Khavinson et al. (2005) proposed that regulatory peptides bind DNA in a manner analogous to transcription factors; their complementary-binding model singled out the base-pair block ATTTTC, which they reported finding repeatedly — with its reverse complement — in the telomerase promoter region. Later work by Khavinson et al. (2020) reported that AEDG raised Nestin, GAP43, β-tubulin III and doublecortin mRNA 1.6–1.8-fold in human gingival mesenchymal stem cells, with molecular modelling placing the interaction at histone H1/3 and H1/6 sites.
These papers support a mechanistic research question, not one settled pathway. Binding models, gene-expression changes, protein-synthesis observations, telomerase regulation, and ALT activity can coexist without proving a single direct mechanism across cell types. Khavinson et al. (2020) review short-peptide regulation of cell differentiation and provide the program-level hypothesis, but a review from the originating network should be read as a synthesis of that program, not independent target confirmation.
| Claim layer | What was studied | Responsible wording |
|---|---|---|
| Telomerase / telomeres | Cultured human somatic cells and later human cell lines. | Reported in specified in-vitro systems; not human clinical longevity evidence. |
| DNA binding | Peptide-DNA interaction proposal under a defined experimental approach. | Proposed mechanism; not a universal transcription-factor role. |
| Gene/protein expression | Named cell models and endpoints. | Model-specific expression observations; not proof of organism-level benefit. |
What Do the Melatonin and Pineal Studies Show?
The pineal lineage led investigators to endocrine endpoints. Goncharova et al. (2001) measured melatonin and cortisol by enzyme immunoassay in female rhesus monkeys of different ages, reporting stimulated evening melatonin production and a normalized cortisol circadian rhythm in the old animals; the abstract gives direction only, without group or effect sizes. That is an endocrine research signal in a nonhuman-primate model; it does not establish sleep improvement, circadian restoration, or safety in people.
A counterpoint belongs beside the positive result. Djeridane et al. (2003) perifused pineal glands from young (9-week) and old (27-month) male Wistar rats and found no significant effect of the AEDG tetrapeptide on melatonin secretion at 10-4–10-6 M at either age; isoproterenol-stimulated melatonin release was likewise unchanged. Different models, preparations, endpoints, and conditions may explain divergent results, but the null study blocks a universal claim that Epithalon reliably increases or normalizes melatonin.
What Does the Lifespan Literature Show—and Not Show?
The model-organism papers are genuine lifespan experiments, but they remain far below a human-longevity tier. Khavinson et al. (2000) dosed Drosophila melanogaster Canton-S through the culture medium at the egg-to-larva stage only and reported an 11–16% increase in imago lifespan — effective from 0.001×10-6 to 5×10-6 wt.% of medium in males and from 0.01×10-6 to 0.1×10-6 wt.% of medium in females — with the increase not tracking dose. Vinogradova et al. (2007) gave female rats 0.1 µg five days a week from four months of age: lifespan was unchanged under the standard light regimen, while under natural and constant illumination maximum lifespan rose by 95 and 24 days respectively, and spontaneous-tumor development was inhibited only in the natural-light group.
Tumor-prone animal models add a risk-relevant research dimension but not a human anticancer conclusion. Anisimov et al. (2002) injected female FVB/N HER-2/neu transgenic mice with 1 µg on five consecutive days each month from two months of age, reporting a reduced cumulative tumor count and maximum tumor size (p<0.05), smaller lung metastases, and a 3.7-fold lower HER-2/neu mRNA level in mammary tumors. The strain, model design, exposure, and originating research network must stay attached to that result: it does not show that Epithalon prevents or treats cancer in people.
The defensible synthesis is narrower than the popular summary: cultured-cell telomerase and division-limit findings, animal endocrine observations, and model-organism lifespan endpoints. The set contains no robust controlled evidence that Epithalon lengthens human life, improves healthspan, or reverses aging.
| Model and species | Endpoint | Reported result | Source |
|---|---|---|---|
| Female FVB/N HER-2/neu transgenic mice; 1 mg subcutaneously 5 times a week from the 2nd month of life to death (dose as printed in the indexed abstract; the sibling reports 12428286 and 12209581 state 1 µg) | Mean and maximum lifespan; number of mice free of breast tumors | Mean lifetime +13.5% (p<0.05); maximum lifetime +13.9%; mean lifetime of the animals without neoplasms +34.2% (p<0.05). The count of tumor-free animals is a separate figure: 3.7-fold more mice remained free of breast tumors (p<0.05) | PMID 12459848 |
| Female FVB HER-2/neu transgenic mice; 1 µg subcutaneously on 5 consecutive days each month, starting from the 2nd month of life | Breast-adenocarcinoma size | Maximum tumor size 33% below control (p<0.05) | PMID 12428286 |
| Mouse heart, cDNA microarray of 15,247 clones; the abstract reports no strain, sex, group size, dose or treatment duration | Gene expression | Epithalon alone changed expression of 98 clones by more than 2-fold. The 6.61-fold maximum activation belongs to the pooled “Epithalon alone or in combination with Vilon” set (194 clones activated, 48 inhibited, maximum inhibition 2.71-fold), not to Epithalon monotherapy, for which the abstract states no maximum fold-change | PMID 12360356 |
| In-silico docking, 26 ultrashort peptides vs 8,400 di/tripeptides | LAT1, LAT2, PEPT1 transporter binding | The 26-peptide biologically active set, which includes AEDG, scored systematically higher than di- and tripeptides with no established biological activity. No AEDG-specific binding score is reported, and the peptides named as the most effective ligands are ED, DS, DR, EDR, EDG, AEDR, AEDL, KEDP and KEDG — not AEDG. Modelling only; no measured cellular uptake | PMID 36979488 |
| Rats, two-arm design — intact animals and animals given single whole-body gamma-irradiation at 6 Gy; the abstract reports no strain, sex, group size, Epithalon dose or dosing schedule | Thymus, spleen and duodenum morphometry | Epithalon slowed duodenal-mucosa metabolism and suppressed splenic hemopoiesis and lymphopoiesis. Direction only: the abstract reports no quantitative result, and does not state which arm produced the effect | PMID 11427924 |
Reading this table: each row is a separate study with its own species, model, exposure and endpoint, so the figures are not comparable across rows. None of the indexed abstracts report group sizes, so every magnitude here is stated without a sample size (n).
How Should Researchers Evaluate an Epithalon Material Record?
A four-residue sequence is not automatically stable, pure, bioactive, or fit for a given experiment. Evaluate the actual form, lot, analytical method, handling history, controls, and acceptance criteria rather than inferring material performance from chain length.
- Identity: confirm the AEDG sequence, form, formula, molecular weight, and registry mapping across protocol and lot record.
- HPLC: examine method, detector, integration, system suitability, and the chromatogram. The guide to HPLC peptide-purity testing explains what peak-area percentage cannot establish.
- Mass spectrometry: use molecular-mass data as orthogonal identity evidence; a mass match alone does not establish purity, sterility, activity, or efficacy.
- Traceability: match lot, date, method, result, laboratory, and document identifiers. The peptide COA guide gives a field-by-field framework.
- Handling: follow lot-specific documentation and an approved institutional SOP; general principles are in the peptide storage guide. This article does not create a solution shelf life.
What is Epithalon’s regulatory status?
This guide does not determine Epithalon’s regulatory status. The peptide originated in a Russian research program, and the sources reviewed here — PubMed-indexed research literature — record no marketing authorization and do not establish its regulatory classification in any jurisdiction; that status should be treated as unverified pending a first-party regulatory record rather than as a confirmed absence of approval. Apex releases research-grade Epithalon against a ≥99% purity specification by reversed-phase HPLC with mass-spectrometric identity confirmation and a per-lot certificate of analysis — a material release criterion, not a clinical qualification.
The current Epithalon product record is the separate destination for live commercial and lot-specific information. Price, stock, variants, shipping, current-batch results, and product specifications are intentionally not cached in this evergreen guide and require same-day first-party verification.
Frequently Asked Questions
Are Epithalon and Epitalon the same peptide?
Yes. Epithalon and Epitalon are spelling variants used for the AEDG tetrapeptide, Ala-Glu-Asp-Gly. PubChem maps the substance to CID 219042, formula C14H22N4O9, computed molecular weight 390.35 g/mol, and CAS RN 307297-39-8. Those fields establish identity, not activity, longevity, safety, efficacy, or approval.
Does Epithalon activate telomerase?
Cultured-cell papers report telomerase, telomere, and division-limit observations, and a 2025 cell-line study reported context-dependent telomerase-upregulation or ALT findings. These are in-vitro results: they do not establish whole-body telomere maintenance, a clinical anti-aging effect, or longer human life.
What human longevity evidence exists for Epithalon?
None is established in the selected source set. The record is cultured-cell experiments, animal endocrine studies, Drosophila and rat lifespan models, and tumor-prone mouse research. Human-derived cells are not a human clinical study, and model-organism lifespan does not establish human lifespan.
Does Epithalon increase melatonin?
The evidence is mixed and model-specific. One old-monkey study reported melatonin and cortisol observations, while a young- and old-rat pineal study reported no significant melatonin effect. The record does not support a universal claim that Epithalon reliably increases or normalizes melatonin.
Why does source concentration matter?
Many primary Epithalon papers share originating investigators, collaborators, or connected institutions. A coherent program generates hypotheses and repeated model findings, but repeated authorship is not independent replication. Examine design, model, methods, sample size, endpoints, and outside confirmation rather than treating publication count as proof.
Research Use Disclaimer
This article is provided for educational and research reference purposes only. Epithalon and all products sold by Apex Laboratory are intended exclusively for in-vitro and preclinical laboratory research and are not for human consumption, veterinary use, diagnosis, treatment, anti-aging use, or administration. Researchers should consult the cited primary literature, current institutional SOPs, and lot-specific analytical records for complete methods and limitations.
